Nectin Therapeutics

Nectin Therapeutics is a biotechnology company dedicated to transforming the lives of cancer patients by pioneering the development of the next generation of immuno-oncology (IO) therapies. Our differentiated treatments have the potential to set new standards for efficacy and patient response rates across various refractory cancers. Founded in 2017, the company is based on groundbreaking research from The Hebrew University of Jerusalem and the University of Rijeka. Our technology addresses major escape mechanisms of current IO treatments through a variety of novel monoclonal antibodies and antibody-drug conjugates.